Would you include carboplatin with an anthracycline and taxane for neoadjuvant treatment for triple negative inflammatory breast cancer?

It's important to talk about such an option that exists if the patient is young and does not have major comorbidities. But, adding the carboplatin for the TN-IBC is not absolutely required. The IBC experts have had multiple discussions about this issue.

There are some data in the non-IBC setting about improving the pCR rate by carboplatin, but it does not mean adding carboplatin is a standard of care. There is no sufficient data on whether it will improve overall survival.

Of course, if the KEYNOT...